Victory Capital Management Inc. Boosts Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Victory Capital Management Inc. lifted its stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 400.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 81,460 shares of the company's stock after acquiring an additional 65,168 shares during the period. Victory Capital Management Inc.'s holdings in Dr. Reddy's Laboratories were worth $1,286,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. POM Investment Strategies LLC lifted its position in shares of Dr. Reddy's Laboratories by 400.0% during the 4th quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock valued at $36,000 after acquiring an additional 1,820 shares during the period. Glenmede Trust Co. NA bought a new position in shares of Dr. Reddy's Laboratories in the third quarter valued at $207,000. Sierra Ocean LLC bought a new position in shares of Dr. Reddy's Laboratories in the fourth quarter valued at $43,000. Allworth Financial LP lifted its stake in shares of Dr. Reddy's Laboratories by 447.8% in the fourth quarter. Allworth Financial LP now owns 2,728 shares of the company's stock valued at $41,000 after buying an additional 2,230 shares in the last quarter. Finally, Independence Bank of Kentucky lifted its stake in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock valued at $44,000 after buying an additional 2,220 shares in the last quarter. Institutional investors and hedge funds own 3.85% of the company's stock.

Dr. Reddy's Laboratories Stock Up 1.1 %

Shares of Dr. Reddy's Laboratories stock traded up $0.15 during trading hours on Friday, reaching $13.73. The company's stock had a trading volume of 1,569,630 shares, compared to its average volume of 1,262,926. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The stock's fifty day simple moving average is $13.66 and its two-hundred day simple moving average is $14.69. Dr. Reddy's Laboratories Limited has a one year low of $12.50 and a one year high of $16.89. The company has a market capitalization of $11.46 billion, a P/E ratio of 21.86 and a beta of 0.48.

Remove Ads

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, research analysts forecast that Dr. Reddy's Laboratories Limited will post 0.8 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a research note on Friday, December 6th. Nomura lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.